SCHEDULE 13D/A: Paul B. Manning and Affiliates Increase Stake in Taysha Gene Therapies to 9.8% Following Recent Share Acquisitions

Paul B. Manning and a group of affiliated entities have increased their beneficial ownership in Taysha Gene Therapies, Inc. to 9.8% of the outstanding common stock through recent purchases in public offerings.

Summary

• Paul B. Manning and affiliated entities (the "Reporting Persons") collectively beneficially own 25,601,111 shares of Taysha Gene Therapies, Inc. common stock, representing 9.8% of the Issuer's outstanding shares.
• This percentage is calculated based on 214,661,715 shares outstanding as of May 15, 2025, plus 46,868,687 shares issued in a public offering that closed on May 30, 2025, totaling 261,530,402 shares.
• On May 30, 2025, BKB Growth Investments, LLC, an affiliate, purchased 750,000 shares in an underwritten public offering for an aggregate price of $2.06 million.
• On June 27, 2024, Mr. Manning purchased 1,333,333 shares in an underwritten public offering for $3.0 million, which were subsequently transferred to other Reporting Persons for no additional consideration.
• The funds used for these acquisitions were sourced from Mr. Manning's personal funds.
• This filing is Amendment No. 3 to the original Schedule 13D filed on October 5, 2020, with previous amendments on November 2, 2022, and August 16, 2023.

Sentiment

Score: 7

Explanation: The document is a factual report of increased beneficial ownership by a significant investor group. The increase in stake by Paul B. Manning and affiliated entities could be viewed as a positive signal of confidence in the issuer, Taysha Gene Therapies, Inc.

Positives

• Increased stake by a significant investor group, potentially signaling confidence in the company's long-term prospects.
• Paul B. Manning, a private equity investment firm CEO, is increasing his personal and affiliated entities' exposure to the company, indicating continued support.

Future Outlook

NA

Industry Context

NA

Legal Proceedings

• None of the Reporting Persons have been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• None of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Related Party Transactions

• Shares purchased by Mr. Manning on June 27, 2024, were subsequently transferred to other Reporting Persons (The Paul B. Manning Revocable Trust, The PBM 2023 Grantor Retained Annuity Trust, The PBM 2025 Grantor Retained Annuity Trust, BKB Growth Investments, LLC, and BKB G2 Investments, LLC) for no additional consideration. This indicates internal transfers within the affiliated group.

Stakeholder Impact

• Shareholders: The increased stake by a significant investor group could be perceived positively, potentially indicating confidence in the company's future. The public offering itself dilutes existing shareholders but provides capital to the company.
• Company (Taysha Gene Therapies): The capital raised through the public offering provides funding for operations and strategic initiatives. The continued investment by a major shareholder group demonstrates ongoing support.

Key Dates

Keywords

Taysha Gene Therapies, TSHA, Paul B. Manning, Schedule 13D, beneficial ownership, equity stake, gene therapy, biotechnology, public offering, investment, share acquisition